Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Corinne Jeanne1, Isabelle Treilleux2, Marie-Aude Le Frère-Belda3

  • 1Laboratoire d'anatomie et cytologie pathologiques, CLCC Baclesse, 14000 Caen, France.

Bulletin Du Cancer
|August 12, 2023
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Technical recommendations from a large-scale French Delphi consensus: A step toward European harmonization of ctDNA analysis.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Changes in Cyclin E1 expression and CCNE1 amplification in high-grade ovarian carcinomas post-PARP inhibitor exposure.

British journal of cancer·2026
Same author

Immuno-molecular features associated with exceptional recurrence-free survivorship from Ovarian Cancer in the pre-PARP era.

NPJ genomic medicine·2026
Same author

[Corrigendum to: "French recommendations for clinical practice, Nice/Saint-Paul-de-Vence 2024-2025: Management of high-grade ovarian epithelial cancer" [Bull Cancer 2026;113:191-207]].

Bulletin du cancer·2026
Same author

Predictive biomarkers of response to immune checkpoint inhibitors in mismatch repair-deficient endometrial cancer.

Therapeutic advances in medical oncology·2026
Same author

Genetic variant interpretation in tumours in the French national ring trials Gen&Tiss - main criteria of improvement.

Virchows Archiv : an international journal of pathology·2026
Same journal

[Update: Evolution in the management of metastatic urothelial carcinomas].

Bulletin du cancer·2026
Same journal

[ONCONNECTE À L'EMPLOI, feedback after three years of a program to prepare for returning to work after cancer in Franche-Comté].

Bulletin du cancer·2026
Same journal

[Off-label use of venetoclax in myeloma].

Bulletin du cancer·2026
Same journal

[Cemiplimab - Adjuvant treatment for the cutaneous squamous cell carcinomas with high risk of relapse, operated and treated by radiotherapy].

Bulletin du cancer·2026
Same journal

Real-world outcomes and management of endometrial cancer in France from 2016 to 2021 (MOONBEAM study).

Bulletin du cancer·2026
Same journal

[Cardiotoxicity in children and adolescents with acute leukemia: Recommendations from the Leukemia Committee of the French Society of Childhood Cancer (SFCE)].

Bulletin du cancer·2026
See all related articles
This summary is machine-generated.

New French clinical practice guidelines emphasize histomolecular diagnosis for endometrial carcinomas. Integrating molecular classification, including mismatch repair (MMR) proteins, p53, and POLE status, impacts treatment decisions for localized and advanced disease.

Area of Science:

  • Gynecologic Oncology
  • Pathology
  • Molecular Diagnostics

Background:

  • Endometrial carcinoma characterization is evolving with molecular classification.
  • Molecular data significantly impacts therapeutic decisions in both localized and advanced stages.
  • Accurate histomolecular diagnosis is crucial for personalized treatment strategies.

Purpose of the Study:

  • To present the 2022-2023 French recommendations for the histomolecular diagnosis of endometrial carcinomas.
  • To outline the mandatory and recommended molecular markers for improved patient management.
  • To guide the integration of molecular findings into clinical practice.

Main Methods:

  • Adherence to WHO 2020 classification for histological typing and grading.
  • Analysis of mismatch repair (MMR) proteins, p53, and POLE status.
Keywords:
CarcinomeClassificationEndometrialInstabilitéMicrosatelliteMolecularMutationPOLE mutationPractice guidelinesRecommandationscarcinomaclassificationde l'endomètredu gène POLEinstabilitymicro-satellitairemoléculairepratiques

Related Experiment Videos

  • Standardized sampling and preparation protocols for comprehensive molecular analysis.

    • Main Results:

    • Mandatory information includes histological type, grade, hormone receptor status, and molecular classification.
    • Key molecular markers are MMR protein status, p53 status, and POLE status in select cases.
    • Guidelines provide precise techniques and interpretation rules for MMR/MSI profiling.

    Conclusions:

    • Histomolecular diagnosis, incorporating molecular classification, refines endometrial carcinoma characterization.
    • Molecular profiling, including MMR, p53, and POLE status, is essential for therapeutic decision-making.
    • Oncogenetics consultation is recommended for specific molecular profiles and patient histories.